Cerebral infarction is ischemic necrosis or softening of limited brain tissue due to impaired blood circulation, ischemia and hypoxia in the brain. Drug treatment for cerebral infarction should be tailored to different periods and different etiologies by selecting the appropriate drugs. The most important of them are anti-platelet aggregation drugs, mainly including aspirin, clopidogrel, cilostazol, tegretol, etc. These drugs inhibit platelet aggregation and release, so that the local thrombus no longer progresses and expands, and they are the basic drugs for the treatment of cerebral infarction. For cerebral infarction caused by atrial fibrillation considering arterial embolism, anticoagulant drugs are often applied to prevent re-embolism. The commonly used oral anticoagulant drug is warfarin, which requires INR monitoring (control at 2.0-3.0), but there are some new oral anticoagulants such as dabigatran, which do not require INR monitoring. As patients with cerebral infarction are often accompanied by high-risk factors such as hypertension, diabetes, hyperlipidemia and hyperhomocysteinemia, these risk factors should be controlled at the same time, and appropriate antihypertensive drugs, hypoglycemic drugs and lipid-lowering drugs should be applied under the guidance of doctors, among which statins are usually used for lipid-lowering drugs, and the combination of folic acid and vitamin B12 should be chosen for homocysteine lowering. In addition, some drugs, such as circulation improvement and neurotropic drugs, can also play a supplementary therapeutic role. In conclusion, drug therapy is only one aspect of cerebral infarction treatment, and the treatment of cerebral infarction should be individualized for the etiology and the risk factors of cerebrovascular disease present in the patient to choose an individualized treatment plan, comprehensive treatment under the guidance of doctors and regular review.